🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchClinicalTrials.gov GLP-1 trial tracker — updated weekly Page 7

ClinicalTrials.gov GLP-1 trial tracker — updated weekly

TrialTracker_MD Mon, Feb 26, 2024 at 4:00 PM 411 replies 11,865 viewsPage 7 of 20
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Jun 13, 2024 at 4:06 PM#31
TrialTracker_MD said:
Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have.

Pushing back on TrialTracker_MD here. Filing an objection on the n=1 problem. Personal experience is genuine evidence about one person and very weak evidence about anybody else, and this thread keeps promoting the first into the second.

9 7steve_okc, dave_SLC, FDA_TrackerJim and 6 others
Reply Quote Save Share Report
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
Jun 22, 2024 at 4:09 AM#32
TrialTracker_MD said:
Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have.

That is right, and it stops being right at the edges. The general case is well behaved; the interesting cases in this thread are all at the boundary where the general case breaks.

Last edited: Jun 22, 2024 at 9:09 AM
10 8lucas_SP_BR, lisa_labSD, adam_van and 7 others
Reply Quote Save Share Report
GraceAZ_72
Member
156
678
Jan 2025
Tucson, AZ
Jun 30, 2024 at 4:07 PM#33
TrialTracker_MD said:
Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have.

Bookmarking. The distinction being drawn above is the one nobody else makes. Sending this to two other people who asked me the same thing last week.

11 9SallyK_inj, CryptoCarl, MariaRD and 8 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Jul 9, 2024 at 4:00 AM#34

From the other side of the consultation, briefly. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

12 10Dr.SurgeonPGH, rachel_ABQ, traveltech_sara and 9 others
Reply Quote Save Share Report
AussieAnna
Member
678
2,890
Jun 2024
Sydney, AU
Jul 17, 2024 at 3:48 PM#35
Dr.Martinez said:
The useful move here is to separate what is established from what is widely repeated.

Second this. I had assumed I was the exception until I read this.

13 11pete_manc_UK, anna.melb_AU, mark_tokyo and 10 others
Reply Quote Save Share Report
15678920

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register